Avalo Therapeutics (AVTX) Stock Price, News & Analysis

Company Overview

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction. These clinical and preclinical assets are supported by a broader research portfolio exploring additional targets in inflammation, tissue remodeling and metabolic regulation. Avalo conducts in-house research at its headquarters in Redwood City, California, and collaborates with academic and industry partners across North America and Europe.

Founded in 2014, Avalo Therapeutics has assembled a management team with deep expertise in drug discovery, clinical development and commercialization. The leadership includes executives and scientists who have held senior roles at leading pharmaceutical and biotechnology firms, providing strategic guidance and operational experience as the company advances its pipeline. Avalo’s governance structure and advisory board further support rigorous scientific evaluation and cultural alignment with industry best practices.

With its integrated research capabilities, external partnerships and a focused pipeline of innovative candidates, Avalo Therapeutics aims to advance multiple programs toward late-stage clinical trials and ultimately deliver new treatment options for patients suffering from chronic cardiometabolic and inflammatory disorders.

Key Stats

• Today's Range: $17.55 to $18.53
• 50-Day Range: $12.74 to $19.96
• 52-Week Range: $6.21 to $24.27
• Volume: 800,235 shs
• Average Volume: 1.51 million shs
• Market Capitalization: $975.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $45.80
• Consensus Rating: Moderate Buy

Avalo Therapeutics Stock Analysis - MarketRank™

Avalo Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 299th out of 837 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Avalo Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on no strong buy ratings, 13 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Avalo Therapeutics has a consensus price target of $45.80, representing about 148.4% upside from its current price of $18.44.

Amount of Analyst Coverage

Avalo Therapeutics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Avalo Therapeutics are expected to grow in the coming year, from ($2.58) to ($2.49) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Avalo Therapeutics is -3.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Avalo Therapeutics is -3.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Avalo Therapeutics has a P/B Ratio of 4.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

25.09% of the float of Avalo Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Avalo Therapeutics has a short interest ratio ("days to cover") of 10.68, which indicates bearish sentiment.

Change versus previous month

Short interest in Avalo Therapeutics has recently increased by 3.01%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Avalo Therapeutics does not currently pay a dividend.

Dividend Growth

Avalo Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.50

News Sentiment

Avalo Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Avalo Therapeutics this week, compared to 3 articles on an average week.

Search Interest

1 people have searched for AVTX on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Avalo Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,762,722.00 in company stock.

Percentage Held by Insiders

4.46% of the stock of Avalo Therapeutics is held by insiders.

Percentage Held by Institutions

87.06% of the stock of Avalo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/13/2026
• Today: 7/25/2026
• BTIG Annual Biotechnology Conference 2026: 7/29/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AVTX
• CIK: 1534120
• Web: www.avalotx.com
• Phone: (410) 522-8707
• Fax: N/A
• Employees: 40
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Avalo Therapeutics: $45.80
• High Price Target: $60.00
• Low Price Target: $34.00
• Potential Upside/Downside: +148.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.46)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$78.26 million
• Net Margins: N/A
• Pretax Margin: -143,340.69%
• Return on Equity: -97.54%
• Return on Assets: -72.42%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.66
• Quick Ratio: 7.66

Sales & Book Value

• Annual Sales: $60 thousand
• Price / Sales: 16,257.93
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.49 per share
• Price / Book: 4.11

Miscellaneous

• Outstanding Shares: 52,900,000
• Free Float: 50,544,000
• Market Cap: $975.48 million
• Optionable: Not Optionable
• Beta: 0.78